Stable Chronic Obstructive Pulmonary Disease

1. Clinical Overview

Summary

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable chronic respiratory condition characterised by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities. [1] It represents a major global health burden, being the third leading cause of death worldwide. [2] The hallmark diagnostic feature is post-bronchodilator spirometry demonstrating an FEV1/FVC ratio of less than 0.70, which defines the presence of persistent airflow limitation. [1]

COPD is primarily caused by exposure to noxious particles or gases, most commonly from tobacco smoking in high-income countries and biomass fuel combustion in low- and middle-income countries. [1,2] The disease is characterised by chronic inflammation affecting the airways, lung parenchyma, and pulmonary vasculature, leading to progressive structural changes including small airway remodelling and parenchymal destruction (emphysema). [3]

The clinical course is marked by progressive dyspnoea, chronic cough, and sputum production, punctuated by acute exacerbations that accelerate disease progression and contribute significantly to morbidity and mortality. [4] Management is multifaceted, encompassing smoking cessation (the single most effective intervention), pharmacotherapy with inhaled bronchodilators and corticosteroids, pulmonary rehabilitation, vaccination, and in advanced cases, long-term oxygen therapy or surgical interventions. [1,5]

Key Facts

• Definition: Persistent airflow limitation (post-bronchodilator FEV1/FVC less than 0.70) with chronic respiratory symptoms [1]
• Global Prevalence: Affects approximately 10% of adults aged over 40 years in high-income countries [6]
• Mortality: Third leading cause of death globally, responsible for 3.23 million deaths annually [2]
• Primary Risk Factor: Tobacco smoking accounts for 85-90% of cases in developed nations [7]
• Genetic Cause: Alpha-1 antitrypsin deficiency accounts for 1-2% of cases, particularly in younger patients [8]
• Gold Standard Diagnosis: Post-bronchodilator spirometry demonstrating FEV1/FVC less than 0.70 [1]
• Severity Classification: GOLD 1-4 based on FEV1 percentage predicted; ABCD based on symptoms and exacerbation history [1]
• Most Effective Intervention: Smoking cessation - only intervention proven to reduce FEV1 decline rate [9]
• Pharmacotherapy: Stepwise approach: long-acting bronchodilators (LAMA/LABA) ± inhaled corticosteroids [10,11]
• Prognosis: Progressive disease; average FEV1 decline 30-50 mL/year in COPD vs 20-30 mL/year in healthy adults [9]
• BODE Index: Multidimensional grading system (BMI, Obstruction, Dyspnoea, Exercise) predicts mortality better than FEV1 alone [12]

Clinical Pearls

Smoking Cessation Pearl: Smoking cessation is THE most important intervention in COPD management. It is the only intervention proven to slow the accelerated decline in FEV1 and reduce mortality. Even patients with severe COPD benefit from quitting. [9] Offer pharmacotherapy (varenicline, bupropion, or nicotine replacement) plus behavioural support to maximise quit rates.

Spirometry Pearl: Diagnosis MUST be confirmed with POST-bronchodilator spirometry. Pre-bronchodilator values can misclassify asthma as COPD. FEV1/FVC less than 0.70 defines obstruction; FEV1 percentage predicted determines severity grade. Reversibility testing (> 12% and > 200mL FEV1 improvement) helps differentiate asthma, but partial reversibility does not exclude COPD. [1]

ICS Controversy Pearl: Inhaled corticosteroids (ICS) should NOT be used routinely in all COPD patients. Evidence supports ICS only in patients with frequent exacerbations (≥2 moderate or ≥1 severe per year) AND blood eosinophil count ≥300 cells/μL. [10,11] ICS increases pneumonia risk by approximately 50% in COPD. [13] The indiscriminate "triple therapy" approach is being reconsidered. [11]

Pulmonary Rehabilitation Pearl: Pulmonary rehabilitation is one of the most effective non-pharmacological interventions - it improves exercise capacity, reduces dyspnoea, enhances health-related quality of life, and reduces hospital admissions. [14] Yet it remains vastly underutilised. Benefits are seen regardless of disease severity. Minimum 6-8 weeks, 2-3 sessions per week.

Oxygen Therapy Pearl: Long-term oxygen therapy (LTOT) improves survival in patients with severe hypoxaemia (PaO2 less than 7.3 kPa or 55 mmHg). [15] However, oxygen does NOT improve survival or hospitalisation rates in patients with moderate desaturation (SpO2 89-93%). [16] LTOT requires ≥15 hours daily use to confer mortality benefit. Recent evidence suggests 24-hour use may not be superior to 15 hours. [15]

GOLD ABCD Pearl: The GOLD ABCD classification underwent major revision. Previous versions used FEV1 to determine groups; current classification uses only symptom burden (CAT/mMRC) and exacerbation history. This creates four groups: A (low symptoms, low exacerbation risk), B (high symptoms, low risk), C (low symptoms, high risk - now rare), D (high symptoms, high risk). [1] However, spirometric severity (GOLD 1-4) is still separately reported and guides referral decisions.

Exacerbation Prevention Pearl: Frequent exacerbations (≥2/year) identify a high-risk phenotype requiring escalated therapy. These patients benefit from LAMA+LABA combination, with ICS added if eosinophils ≥300. [10] Azithromycin prophylaxis (250mg three times weekly or 500mg three times weekly) reduces exacerbation frequency in carefully selected patients, but requires ECG (QTc monitoring) and microbiology review due to antibiotic resistance concerns. [17]

---

2. Epidemiology

Global Burden

COPD represents a major and growing global health challenge. It is the third leading cause of death worldwide, responsible for an estimated 3.23 million deaths annually. [2] The global prevalence among adults aged 30 years and older is approximately 10.3%, though this varies substantially by region, with higher rates in areas with high smoking prevalence and biomass fuel exposure. [6]

In high-income countries, COPD affects approximately 10-15% of adults aged over 40 years. [6] However, the disease remains substantially underdiagnosed, with studies suggesting that 50-70% of patients with spirometric evidence of COPD have not received a formal diagnosis. [18] This diagnostic gap represents a significant public health challenge, as early intervention can modify disease progression.

The economic burden is substantial. In the United States alone, COPD costs exceed $50 billion annually in direct and indirect costs, including healthcare utilisation, lost productivity, and disability. [19] Hospital admissions for acute exacerbations account for the majority of healthcare expenditure in COPD.

Demographics

Age: COPD prevalence increases dramatically with age. While relatively uncommon below age 40 (except in alpha-1 antitrypsin deficiency), prevalence rises steeply thereafter, affecting approximately 10% of those aged 40-50, 15-20% of those aged 60-70, and up to 25% of those over 75 years. [6]

Sex: Historically more common in men due to higher smoking rates, the sex distribution has equalised in many high-income countries as female smoking rates increased. In some regions, COPD prevalence is now higher in women, who may be more susceptible to tobacco-induced lung damage for equivalent smoke exposure. [20] Women also tend to develop disease at younger ages and with less cumulative smoke exposure.

Socioeconomic Status: COPD disproportionately affects individuals of lower socioeconomic status, related to higher smoking rates, occupational exposures, indoor air pollution, and reduced access to healthcare. [7]

Geography: Prevalence varies globally, with highest rates in regions with high smoking prevalence (Eastern Europe, East Asia) and areas with significant biomass fuel exposure (Sub-Saharan Africa, South Asia). [2]

Risk Factors

Mortality and Morbidity

COPD mortality rates have shown divergent trends: declining in many high-income countries due to reduced smoking prevalence and improved management, but rising in low- and middle-income countries due to increasing tobacco use and persistent biomass fuel exposure. [2]

Prognosis is highly variable and depends on multiple factors beyond FEV1, including:

• Exacerbation frequency and severity
• Degree of dyspnoea
• Exercise capacity
• Comorbidity burden (cardiovascular disease, osteoporosis, depression, lung cancer)
• Nutritional status (BMI)
• Continuation of smoking

The BODE index (Body mass index, Obstruction, Dyspnoea, Exercise capacity) provides superior prognostic discrimination compared to FEV1 alone. [12]

---

3. Pathophysiology

Molecular and Cellular Mechanisms

COPD is fundamentally an inflammatory disorder characterised by an abnormal, amplified inflammatory response to chronic inhalation of noxious particles and gases. [3] The pathophysiology involves complex interactions between environmental exposures, inflammatory processes, and host susceptibility factors.

Inflammatory Cascade:

Tobacco smoke and other irritants activate epithelial cells and resident macrophages in the airways and alveoli, triggering release of chemotactic factors (IL-8, LTB4, TNF-α) that recruit neutrophils, macrophages, and CD8+ T lymphocytes. [3] This inflammatory infiltrate releases:

• Proteases: Neutrophil elastase, matrix metalloproteinases (MMPs), cathepsins
• Reactive oxygen species (ROS): Contributing to oxidative stress
• Inflammatory mediators: TNF-α, IL-1β, IL-6, IL-8

Protease-Antiprotease Imbalance:

The balance between tissue-degrading proteases (neutrophil elastase, MMPs) and protective antiproteases (alpha-1 antitrypsin, tissue inhibitors of metalloproteinases) is disrupted, favouring proteolytic destruction of elastin and collagen in alveolar walls - the pathological hallmark of emphysema. [3] Alpha-1 antitrypsin deficiency represents the extreme example of this imbalance.

Oxidative Stress:

Both tobacco smoke (containing 10^15 oxidants per puff) and activated inflammatory cells generate ROS, overwhelming endogenous antioxidant defences (superoxide dismutase, glutathione). Oxidative stress:

• Inactivates antiproteases
• Amplifies inflammation (NF-κB activation)
• Causes direct cellular damage
• Accelerates lung aging (telomere shortening)

Structural Remodelling:

Chronic inflammation drives progressive structural changes:

1. Small Airways (less than 2mm diameter): Goblet cell metaplasia, submucosal gland hypertrophy, smooth muscle hypertrophy, peribronchiolar fibrosis, inflammatory cell infiltration - collectively termed "obstructive bronchiolitis" or "small airways disease". [3]

2. Parenchymal Destruction: Alveolar wall destruction leads to emphysema - permanent enlargement of airspaces distal to terminal bronchioles. Two main patterns:

   • Centrilobular: Affects respiratory bronchioles; upper lobe predominant; associated with smoking
   • Panlobular: Affects entire acinus; lower lobe predominant; associated with alpha-1 antitrypsin deficiency

3. Vascular Changes: Thickening of vessel walls (smooth muscle hypertrophy, intimal hyperplasia), endothelial dysfunction, loss of capillary bed - contributing to pulmonary hypertension and cor pulmonale.

Physiological Consequences

Airflow Limitation:

Multiple mechanisms contribute to the characteristic airflow obstruction:

1. Loss of Elastic Recoil: Emphysematous destruction reduces radial traction on small airways, causing dynamic collapse during expiration (especially on forced expiration)

2. Airway Remodelling: Fibrosis, smooth muscle hypertrophy, and luminal occlusion by mucus and inflammatory exudate in small airways

3. Increased Airway Resistance: Due to luminal narrowing and mucus plugging

The result is a reduced FEV1/FVC ratio (defining obstruction) and reduced FEV1 (defining severity).

Gas Exchange Abnormalities:

• V/Q Mismatch: Predominant mechanism in COPD; areas of low ventilation relative to perfusion cause hypoxaemia; areas of high ventilation relative to perfusion increase dead space
• Diffusion Impairment: Reduced alveolar-capillary surface area in emphysema limits gas transfer
• Alveolar Hypoventilation: In severe disease, leads to hypercapnia (CO2 retention)

Hyperinflation:

Loss of elastic recoil and expiratory flow limitation cause air trapping and increased functional residual capacity (FRC) - termed "static hyperinflation". During exercise, insufficient time for complete exhalation between breaths causes further air trapping - "dynamic hyperinflation". [21]

Consequences of hyperinflation:

• Flattened diaphragm with reduced mechanical advantage
• Increased work of breathing
• Reduced inspiratory capacity
• Exertional dyspnoea

Pulmonary Hypertension and Cor Pulmonale:

Advanced COPD causes pulmonary hypertension through:

• Hypoxic vasoconstriction
• Vascular remodelling and loss of capillary bed
• Increased blood viscosity (polycythaemia)

Right ventricular hypertrophy and eventual failure (cor pulmonale) develops in severe cases.

Clinical Phenotypes

COPD is heterogeneous. Classical teaching described two phenotypes:

However, modern understanding recognises these represent extremes of a spectrum, with most patients exhibiting overlapping features.

Contemporary Phenotype Classification:

1. Frequent Exacerbator: ≥2 exacerbations per year; may relate to bacterial colonisation, increased airway inflammation, or severe airflow obstruction [4]

2. COPD-Asthma Overlap (ACO): Features of both conditions; higher eosinophils; better response to ICS; may represent ~15-20% of COPD patients

3. Emphysema-predominant vs Chronic Bronchitis-predominant: Identifiable on CT imaging; influences treatment (e.g., lung volume reduction surgery for emphysema, mucolytics for chronic bronchitis)

4. Rapid Decliner: Accelerated FEV1 decline (> 60 mL/year); may relate to persistent smoking, recurrent exacerbations, or genetic susceptibility

---

4. Clinical Presentation

Symptoms

COPD typically presents insidiously with gradual symptom progression over years to decades. Many patients attribute symptoms to "normal aging" or "smoker's cough", leading to diagnostic delay.

Cardinal Symptoms:

1. Progressive Dyspnoea:

   • Hallmark symptom; persistent, progressive, worse with exercise
   • Initially only on exertion (climbing stairs, walking uphill)
   • Progressively affects activities of daily living
   • Eventually present at rest in advanced disease
   • Quantified using mMRC (modified Medical Research Council) dyspnoea scale (0-4) or CAT (COPD Assessment Test) score (0-40)

2. Chronic Cough:

   • Often the first symptom; initially intermittent ("smoker's cough")
   • May become persistent; typically worse in mornings
   • Can be non-productive or productive
   • Chronic bronchitis defined as productive cough for ≥3 months/year for ≥2 consecutive years

3. Sputum Production:

   • Often accompanies cough
   • Usually mucoid (white/clear) in stable disease
   • Change in volume, colour (purulent), or consistency suggests exacerbation
   • Chronic purulent sputum may indicate bronchiectasis or bacterial colonisation

4. Wheeze:

   • Expiratory wheeze common
   • May be absent in severe disease (reduced airflow produces less wheeze - "silent chest")

Additional Symptoms:

• Chest tightness: Less specific; overlaps with cardiac disease
• Reduced exercise tolerance: Progressive limitation of physical activities
• Fatigue and muscle weakness: Related to deconditioning, chronic inflammation, hypoxia
• Weight loss: Indicates severe disease; muscle wasting from increased work of breathing and systemic inflammation
• Morning headaches: May suggest nocturnal hypercapnia
• Ankle swelling: Suggests cor pulmonale (right heart failure)

Red Flag Symptoms Requiring Urgent Assessment:

• Haemoptysis: Rule out lung cancer, tuberculosis, bronchiectasis
• Unexplained weight loss: Exclude malignancy
• Severe breathlessness at rest: Consider acute exacerbation, pneumothorax, cardiac cause
• Chest pain: Rule out pneumonia, pneumothorax, acute coronary syndrome, pulmonary embolism

Signs

Physical examination may be entirely normal in mild-to-moderate COPD, particularly if the patient is examined at rest. Signs become more apparent with disease progression.

General Inspection:

• Cachexia: Muscle wasting, low BMI; indicates severe disease and poor prognosis
• Cyanosis: Central cyanosis (tongue, lips) indicates hypoxaemia
• Pursed-lip breathing: Physiological strategy to generate positive end-expiratory pressure, reducing dynamic airway collapse and improving gas exchange
• Use of accessory muscles: Sternocleidomastoid, scalenes; indicates increased work of breathing
• Tripod position: Leaning forward with arms braced; reduces work of breathing by optimising diaphragm mechanics
• Hoover's sign: Paradoxical inward movement of lower ribcage during inspiration; indicates severe hyperinflation with flattened diaphragm

Chest Examination:

Inspection:

• Barrel chest: Increased anteroposterior diameter from hyperinflation
• Reduced chest wall movement: Particularly with severe hyperinflation
• Prolonged expiratory phase: Expiration takes longer than inspiration

Palpation:

• Reduced chest expansion: Symmetrically reduced
• Apex beat: May be difficult to palpate (hyperinflated chest shifts heart downwards)

Percussion:

• Hyperresonant: Increased resonance from hyperinflation
• Loss of cardiac dullness: Hyperinflated lung overlies heart
• Low diaphragm: Reduced upper border of liver dullness

Auscultation:

• Reduced breath sounds: Widespread; "quiet chest"
• Prolonged expiratory phase: Expiration > inspiration
• Wheeze: Expiratory wheeze; may be polyphonic (multiple pitches)
• Coarse crackles: May indicate sputum retention, bronchiectasis, or concurrent infection
• Reduced vocal resonance: From hyperinflation

Signs of Complications:

Cor Pulmonale (Right Heart Failure):

• Raised jugular venous pressure (JVP)
• Peripheral oedema (ankle/sacral)
• Hepatomegaly
• Parasternal heave (right ventricular hypertrophy)
• Loud P2 (pulmonary component of second heart sound)
• Pansystolic murmur at left sternal edge (tricuspid regurgitation)

Hypercapnia (CO2 retention):

• Bounding pulse
• Warm peripheries
• Flapping tremor (asterixis) - indicates severe hypercapnia
• Confusion, drowsiness (CO2 narcosis)
• Papilloedema (rare)

---

5. Investigations

Spirometry (Diagnostic Standard)

Spirometry is essential for COPD diagnosis and cannot be replaced by clinical assessment alone. [1]

Diagnostic Criteria:

A post-bronchodilator FEV1/FVC ratio less than 0.70 confirms the presence of persistent airflow limitation in the appropriate clinical context (symptoms, risk factor exposure). [1]

Key Points:

• Must be performed AFTER bronchodilator administration (typically 400μg salbutamol or equivalent)
• Pre-bronchodilator values may overestimate obstruction
• FEV1/FVC ratio less than 0.70 is a fixed threshold; some advocate using lower limit of normal (LLN) to reduce overdiagnosis in elderly, but GOLD recommends fixed threshold
• FEV1 percentage predicted determines spirometric severity (GOLD grade 1-4)

Bronchodilator Reversibility Testing:

While not required for diagnosis, assessing response to bronchodilator (change in FEV1 > 12% AND > 200mL from baseline) helps:

• Differentiate asthma (typically significant reversibility) from COPD (limited reversibility)
• Identify COPD-asthma overlap (ACO)
• Partial reversibility does NOT exclude COPD

Spirometric Patterns:

GOLD Classification

Spirometric Grades (based on post-bronchodilator FEV1 in patients with FEV1/FVC less than 0.70): [1]

GOLD ABCD Assessment Tool (based on symptoms and exacerbation history): [1]

This classification determines treatment strategy and is INDEPENDENT of spirometric severity.

Symptom Assessment: Use either:

• mMRC (modified Medical Research Council) dyspnoea scale: 0-1 = low symptoms; ≥2 = high symptoms
• CAT (COPD Assessment Test): 0-9 = low symptoms; ≥10 = high symptoms

Exacerbation History (in previous 12 months):

• 0-1 moderate exacerbation (not requiring hospitalisation) = low risk
• ≥2 moderate OR ≥1 severe exacerbation (requiring hospitalisation) = high risk

Additional Pulmonary Function Tests

Arterial Blood Gas (ABG)

Indications:

• FEV1 less than 40% predicted (GOLD 3-4)
• Clinical signs of respiratory failure or cor pulmonale
• Oxygen saturation less than 92% on pulse oximetry
• Suspected hypercapnia

Findings in Stable COPD:

Chest X-Ray

CXR is neither sensitive nor specific for COPD diagnosis but serves to:

• Exclude alternative diagnoses (lung cancer, cardiac failure, pneumonia, pneumothorax)
• Identify complications (bullae, cor pulmonale)

Typical Findings (present in moderate-severe disease):

• Hyperinflation: Flattened diaphragms (below 6th anterior rib), increased retrosternal airspace (> 4.5cm), obtuse costophrenic angles
• Hyperlucent lung fields: Increased radiolucency
• Vascular attenuation: Reduced peripheral vascular markings in emphysema
• Bullae: Air-filled spaces > 1cm diameter
• Cor pulmonale: Enlarged right heart border, prominent pulmonary arteries

IMPORTANT: A normal CXR does NOT exclude COPD.

Computed Tomography (CT) Chest

Not routinely required for diagnosis but indicated for:

• Uncertain diagnosis
• Assessing extent and distribution of emphysema (particularly if considering surgical intervention)
• Excluding alternative/additional pathology (bronchiectasis, lung cancer, interstitial lung disease)
• Pre-operative assessment for lung volume reduction surgery (LVRS) or transplant

Typical Findings:

• Emphysema: Areas of low attenuation without visible walls; classified by distribution (centrilobular, panlobular, paraseptal)
• Airway wall thickening
• Bronchiectasis (may coexist)

Blood Tests

Full Blood Count (FBC):

• Polycythaemia (Hb > 16 g/dL in women, > 18 g/dL in men): Suggests chronic hypoxia; increases blood viscosity and thrombotic risk
• Anaemia: Worsens dyspnoea; check and correct if present
• Eosinophils: Guides ICS therapy; consider ICS if ≥300 cells/μL in exacerbators [10]

Alpha-1 Antitrypsin (AAT) Level:

Indications for Testing: [8]

• Age less than 45 years at COPD diagnosis
• Minimal smoking history (less than 20 pack-years) or never-smoker
• Lower lobe-predominant emphysema
• Family history of early COPD or AAT deficiency
• Unexplained liver disease

Interpretation:

• Normal: > 11 μM (50 mg/dL)
• Deficiency: less than 11 μM
• Severe deficiency (PiZZ phenotype): less than 7 μM; high risk of early emphysema
• If low, proceed to phenotype testing (PiMM normal, PiMZ carrier, PiZZ deficient)

Microbiological Investigations

Sputum Culture:

Indicated for:

• Recurrent exacerbations (> 2-3 per year)
• Suspected bronchiectasis
• Chronic purulent sputum production

May identify bacterial colonisation (Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, Pseudomonas aeruginosa) or atypical organisms.

Electrocardiogram (ECG)

ECG is often abnormal in COPD but findings are non-specific:

Features of Hyperinflation:

• Low voltage QRS complexes
• Rightward axis deviation
• Clockwise rotation (delayed R wave progression in precordial leads)
• P pulmonale (tall P waves in II, III, aVF) - suggests right atrial enlargement

Features of Cor Pulmonale:

• Right ventricular hypertrophy (tall R in V1, deep S in V5-6, right axis deviation)
• Right bundle branch block
• P pulmonale

Other: Atrial arrhythmias (atrial fibrillation, flutter) are more common in COPD.

Echocardiography

Indications:

• Suspected cor pulmonale (signs of right heart failure)
• Suspected left ventricular dysfunction (important differential for dyspnoea)
• Disproportionate dyspnoea for degree of airflow obstruction

Findings:

• Right ventricular dilatation/hypertrophy
• Tricuspid regurgitation
• Estimated pulmonary artery systolic pressure (ePASP)
• Left ventricular systolic/diastolic function (exclude cardiac cause)

Exercise Testing

6-Minute Walk Test (6MWT):

• Simple, standardised test measuring distance walked in 6 minutes
• Component of BODE index
• Assesses functional capacity, guides pulmonary rehabilitation, and monitors response

Cardiopulmonary Exercise Testing (CPET):

• Detailed assessment of exercise limitation
• Differentiates cardiac vs respiratory vs deconditioning causes of dyspnoea
• Useful in selected cases with unclear diagnosis

---

6. Management

Management of stable COPD is multifaceted, combining non-pharmacological interventions (the most important being smoking cessation), pharmacotherapy, and in selected patients, advanced interventions. The goals are to reduce symptoms, improve exercise tolerance and health status, prevent disease progression, and reduce exacerbation frequency and mortality.

Non-Pharmacological Management

Smoking Cessation

Smoking cessation is the SINGLE MOST EFFECTIVE intervention in COPD and the ONLY intervention proven to slow the accelerated decline in FEV1. [9] All clinicians should offer smoking cessation support at every encounter.

Evidence:

• Smoking cessation reduces FEV1 decline from 60-80 mL/year (in continuing smokers with COPD) to 30-40 mL/year (normal age-related decline). [9]
• Reduces exacerbation frequency
• Reduces mortality
• Benefits occur regardless of age or disease severity

Approach:

1. ASK about smoking at every visit
2. ADVISE all smokers to quit (clear, personalised message)
3. ASSESS willingness to quit
4. ASSIST with quit attempt:
   • Behavioural support (individual or group counselling, telephone quitlines)
   • Pharmacotherapy (first-line options):
     • Varenicline: Partial nicotine receptor agonist; most effective single agent (OR 2.3 for sustained abstinence vs placebo)
     • Combination nicotine replacement therapy (NRT): Patch + short-acting form (gum, lozenge, inhaler); effective (OR 1.4)
     • Bupropion: Antidepressant; effective (OR 1.6)
5. ARRANGE follow-up within 1-2 weeks of quit date

Special Considerations:

• E-cigarettes: Emerging evidence suggests potential role as harm-reduction tool, though long-term safety data lacking
• Cannabis cessation: Also important, as cannabis smoking contributes to airway disease

Vaccination

Influenza Vaccine:

• Annual vaccination recommended for ALL COPD patients [1]
• Reduces exacerbations and mortality
• Inactivated vaccine preferred (live attenuated contraindicated in severe disease)

Pneumococcal Vaccine:

• Recommended for ALL COPD patients [1]
• PCV13 (pneumococcal conjugate vaccine) followed by PPSV23 (pneumococcal polysaccharide vaccine) 8 weeks later, or as per national guidelines
• Reduces invasive pneumococcal disease

COVID-19 Vaccine:

• COPD patients at higher risk of severe COVID-19
• Vaccination and boosters recommended

Pertussis (Tdap) Booster:

• Consider in regions with pertussis outbreaks

Pulmonary Rehabilitation

Pulmonary rehabilitation is one of the most effective interventions in COPD, yet vastly underutilised. [14]

Definition: "Comprehensive intervention based on thorough patient assessment followed by patient-tailored therapies that include, but are not limited to, exercise training, education, and behaviour change." [14]

Evidence:

• Improves exercise capacity (6-minute walk distance)
• Reduces dyspnoea
• Improves health-related quality of life
• Reduces hospital admissions and readmissions
• Benefits ALL severity grades
• Effects maintained 6-12 months; booster sessions extend benefits

Indications: All symptomatic COPD patients (typically GOLD B, C, D or GOLD 2-4 spirometrically)

Programme Components:

• Minimum 6-8 weeks
• 2-3 sessions per week
• Endurance and strength training (upper and lower limb)
• Breathing techniques
• Education (disease, medications, self-management)
• Nutritional advice
• Psychological support

Barriers: Poor referral rates, limited availability, patient dropout, lack of maintenance programmes

Physical Activity and Exercise

Beyond formal pulmonary rehabilitation, regular physical activity should be encouraged. Even walking programmes improve functional capacity and reduce exacerbation risk.

Nutritional Support

Underweight Patients (BMI less than 21):

• Associated with worse prognosis (component of BODE index)
• Increased caloric intake with protein supplementation
• Anabolic steroids (limited evidence)

Overweight Patients: Weight reduction improves exercise capacity and reduces dyspnoea

Self-Management Education

Components:

• Understanding the disease
• Correct inhaler technique (critical - up to 70% of patients use inhalers incorrectly)
• Recognising and managing exacerbations (self-management plans with rescue medications)
• Advance care planning

Pharmacological Management

Pharmacotherapy in COPD is stepwise, guided by symptom burden and exacerbation risk (GOLD ABCD classification). [1,10]

Bronchodilators

Bronchodilators are central to symptomatic management. They improve FEV1, reduce hyperinflation, improve exercise capacity, and reduce dyspnoea.

Short-Acting Bronchodilators (Rescue Therapy):

Long-Acting Bronchodilators (Maintenance Therapy):

Combination Therapy:

Inhaled Corticosteroids (ICS)

CRITICAL: ICS should NOT be used routinely in all COPD patients. [10,11]

Evidence Supporting ICS:

• Reduces exacerbation frequency in selected patients (those with frequent exacerbations and elevated eosinophils) [10,11]
• Does NOT modify long-term FEV1 decline
• Does NOT reduce mortality (TORCH trial) [13]

Indications for ICS (must meet BOTH criteria):

1. Frequent exacerbations: ≥2 moderate or ≥1 severe exacerbation per year despite LAMA+LABA
2. Blood eosinophils ≥300 cells/μL (or ≥100 cells/μL with very frequent exacerbations)

Risks of ICS:

• Pneumonia: Increased risk by ~50% (particularly with fluticasone) [13]
• Oral candidiasis
• Hoarse voice
• Possible increased risk of mycobacterial infection, cataracts, osteoporosis (with long-term high-dose use)

ICS Withdrawal: In patients on ICS without appropriate indications (low eosinophils, infrequent exacerbations), ICS can be safely withdrawn without increased exacerbation risk if LAMA+LABA continued. [10]

Stepwise Treatment Algorithm (GOLD 2024) [1]

Group A (Low symptoms, Low exacerbation risk):

• First-line: Bronchodilator monotherapy (LAMA or LABA) PRN or regularly
• If inadequate: Switch to alternative class or escalate to LAMA+LABA

Group B (High symptoms, Low exacerbation risk):

• First-line: LAMA or LABA (LAMA preferred)
• If inadequate: Escalate to LAMA+LABA
• If still inadequate: Consider LAMA+LABA+ICS IF eosinophils ≥300 (though exacerbation risk is low by definition in Group B)

Group C (Low symptoms, High exacerbation risk):

• First-line: LAMA+LABA
• If inadequate: Add ICS (triple therapy) IF eosinophils ≥100
• Alternative: Consider roflumilast, azithromycin

This group is now uncommon with revised GOLD classification.

Group D (High symptoms, High exacerbation risk):

• First-line: LAMA+LABA
• If inadequate: Escalate to triple therapy (LAMA+LABA+ICS) IF eosinophils ≥100 [11]
• If eosinophils less than 100: Consider LAMA+LABA + roflumilast or azithromycin
• Refractory: Consider advanced therapies (see below)

Additional Pharmacotherapy

Roflumilast (PDE4 Inhibitor):

• Oral anti-inflammatory
• Indication: GOLD D patients with chronic bronchitis phenotype (productive cough), FEV1 less than 50%, frequent exacerbations despite LAMA+LABA±ICS
• Reduces exacerbation frequency by ~15-20%
• Side effects: Diarrhoea, nausea, weight loss (common; cause significant dropout)

Azithromycin (Macrolide Prophylaxis):

• 250mg three times weekly or 500mg three times weekly
• Indication: GOLD D patients with very frequent exacerbations (≥3/year) despite optimal inhaled therapy; ex-smokers preferred (continued smoking reduces efficacy) [17]
• Reduces exacerbation frequency by ~25-30%
• Risks: QTc prolongation (require baseline and monitoring ECG), hearing impairment, antibiotic resistance, drug interactions
• Contraindications: QTc > 450ms, NTM colonisation, documented bacterial resistance

Mucolytics (e.g., Carbocisteine, N-acetylcysteine):

• Weak evidence for reducing exacerbations in selected patients (chronic productive cough)
• Not routinely recommended

Theophylline:

• Weak bronchodilator; narrow therapeutic index
• Reserved for patients inadequately controlled on inhaled therapy and unable to use alternative agents
• Requires serum level monitoring (therapeutic range 10-20 mg/L)
• Numerous drug interactions

Oral Corticosteroids:

• NO role in stable COPD management (unlike asthma)
• Reserved for acute exacerbations only
• Chronic use associated with significant morbidity (osteoporosis, myopathy, diabetes, cataracts)

Long-Term Oxygen Therapy (LTOT)

LTOT improves survival in COPD patients with severe chronic hypoxaemia. [15]

Indications (TWO assessments ≥3 weeks apart, stable, on optimal therapy):

1. PaO2 ≤7.3 kPa (55 mmHg) OR SpO2 ≤88% at rest, OR
2. PaO2 7.3-8.0 kPa (55-60 mmHg) OR SpO2 89% WITH:
   • Cor pulmonale (ECG evidence of right ventricular hypertrophy, peripheral oedema), OR
   • Polycythaemia (haematocrit > 55%), OR
   • Pulmonary hypertension (echocardiography)

LTOT does NOT improve outcomes in patients with moderate desaturation (SpO2 89-93%). [16]

Prescription:

• Target: PaO2 > 8 kPa (60 mmHg) OR SpO2 ≥90%
• Duration: ≥15 hours per day (mortality benefit increases with hours of use; historical teaching recommended ≥18 hours, but recent evidence suggests 15-24 hours may be equivalent) [15]
• Flow rate: Titrated to achieve target saturations (typically 1-3 L/min)
• Delivery: Nasal cannulae, concentrator (home), cylinders (portable)

Ambulatory Oxygen: For patients with exercise desaturation but not resting hypoxaemia; improves exercise capacity and dyspnoea during use but no mortality benefit

CRITICAL: Smoking is an ABSOLUTE CONTRAINDICATION to home oxygen (fire risk, continued smoking negates benefit)

Surgical and Interventional Therapies

Lung Volume Reduction Surgery (LVRS):

• Indication: Severe emphysema (GOLD 3-4) with upper lobe predominance and low exercise capacity despite optimal medical therapy and pulmonary rehabilitation
• Surgical resection of most diseased lung regions improves mechanics of remaining lung
• Evidence: NETT trial showed improved survival in selected patients (upper lobe emphysema + low exercise capacity) vs medical therapy
• Risks: Significant operative mortality (5%), complications (prolonged air leak)
• Contraindications: Diffuse emphysema, very low DLCO (less than 20%), pulmonary hypertension, significant comorbidity

Endobronchial Valve Placement:

• Less invasive alternative to LVRS
• One-way valves placed bronchoscopically to collapse targeted lobe
• Indication: Severe heterogeneous emphysema with absent collateral ventilation
• Fewer complications than surgery but lower efficacy

Bullectomy:

• Resection of giant bullae (> 1/3 hemithorax) compressing functioning lung
• Selected patients benefit symptomatically

Lung Transplantation:

• Indications: Very severe COPD (GOLD 4), BODE index ≥7, hypercapnia, pulmonary hypertension, frequent hospitalisations despite maximal therapy
• Consider referral when FEV1 less than 25% or meeting above criteria
• Contraindications: Age > 65 (relative), active smoking, significant comorbidity, poor compliance
• Improves quality of life; survival benefit uncertain

Palliative and End-of-Life Care

Advanced COPD carries high symptom burden and mortality. Palliative care principles should be integrated early.

Symptom Management:

• Dyspnoea: Opioids (morphine 2.5-5mg PO PRN or regular; evidence for benefit in refractory dyspnoea), benzodiazepines (limited evidence, sedation risk), fan to face
• Anxiety/Depression: Common (40% prevalence); SSRIs, psychological support
• Anorexia/Cachexia: Nutritional support

Advance Care Planning: Discussion of prognosis, goals of care, ceiling of treatment, and resuscitation status appropriate for all patients with severe COPD (GOLD 3-4 or frequent hospitalisations)

Non-Invasive Ventilation (NIV) in Stable COPD: Some evidence suggests domiciliary NIV may benefit selected patients with persistent hypercapnia (PaCO2 > 7 kPa) despite optimal therapy, though data conflicting

---

7. Prognosis

COPD is a progressive disease, though the rate of progression varies widely between individuals. Prognosis depends on multiple factors beyond FEV1 alone.

Natural History

FEV1 Decline:

• Healthy non-smokers: ~20-30 mL/year decline after age 30
• Smokers without COPD: ~40-50 mL/year
• Smokers with COPD: ~60-80 mL/year (accelerated decline) [9]
• Smoking cessation slows decline back towards normal rates

Progression is NOT linear: Some patients experience rapid decline ("rapid decliners"), others slow progression. Exacerbation frequency accelerates decline.

Mortality

• 5-year mortality for GOLD 3-4 COPD: 40-50%
• Leading causes of death in COPD patients:
  • Respiratory failure (35%)
  • Cardiovascular disease (25-30%)
  • Lung cancer (15-20%)
  • Other comorbidities (20-30%)

Prognostic Factors

FEV1: Traditionally the main prognostic marker; GOLD grades correlate with mortality, but FEV1 alone is insufficient for comprehensive risk stratification.

BODE Index: [12]

Multidimensional grading system superior to FEV1 for predicting mortality. Scores 0-10; higher score = worse prognosis.

Interpretation:

• BODE 0-2: 80% 4-year survival
• BODE 3-4: 67% 4-year survival
• BODE 5-6: 57% 4-year survival
• BODE 7-10: 18% 4-year survival

Exacerbation Frequency: Frequent exacerbators (≥2/year) have accelerated FEV1 decline, reduced quality of life, and higher mortality. Severe exacerbations requiring hospitalisation carry particularly poor prognosis (up to 25% 1-year mortality post-hospitalisation).

Comorbidities: Cardiovascular disease, lung cancer, osteoporosis, depression, diabetes are more common in COPD and worsen prognosis.

Other Poor Prognostic Markers:

• Severe hypoxaemia or hypercapnia
• Cor pulmonale
• Low BMI (less than 21) or cachexia
• Poor exercise capacity (6MWT less than 350m)
• Continued smoking
• Frequent hospitalisations
• Older age
• Lower socioeconomic status

Complications

Acute Exacerbations:

• Define acute worsening of respiratory symptoms beyond day-to-day variation, requiring treatment change
• Triggered by infections (viral/bacterial), pollution, unknown factors
• Accelerate disease progression and increase mortality
• See separate topic: "Acute Exacerbation of COPD"

Respiratory Failure:

• Type 1 (hypoxaemic): PaO2 less than 8 kPa
• Type 2 (hypercapnic): PaCO2 > 6 kPa
• Chronic compensated type 2 common in advanced COPD

Cor Pulmonale:

• Right ventricular hypertrophy/failure secondary to lung disease
• Presents with peripheral oedema, raised JVP, hepatomegaly
• Associated with poor prognosis

Pneumothorax:

• Spontaneous pneumothorax more common in emphysema (especially bullous disease)
• Requires high clinical suspicion (sudden worsening dyspnoea, chest pain)
• Can be life-threatening

Lung Cancer:

• COPD and lung cancer share tobacco exposure as common risk factor
• COPD itself is independent risk factor for lung cancer (chronic inflammation, genetic susceptibility)
• Annual incidence ~1-2% in COPD patients
• Screen with low-dose CT in high-risk patients (55-80 years, ≥20 pack-year smoking history)

Infections:

• Pneumonia more common and more severe in COPD
• ICS use further increases pneumonia risk [13]

Cardiovascular Disease:

• Ischaemic heart disease, heart failure, arrhythmias, stroke more common in COPD
• Chronic inflammation and shared risk factors
• Cardiovascular disease is leading cause of death in mild-moderate COPD

Osteoporosis:

• Multifactorial: chronic inflammation, reduced activity, corticosteroid use, smoking, vitamin D deficiency
• Fractures cause significant morbidity
• DEXA scan recommended in GOLD 3-4

Depression and Anxiety:

• Affect 40% of COPD patients
• Worsen outcomes (reduced adherence, increased exacerbations, hospitalisations)
• Often under-recognised and undertreated

Cachexia and Muscle Wasting:

• Systemic inflammation, increased work of breathing, reduced activity
• Low BMI independent predictor of mortality (BODE index)

---

8. Differential Diagnosis

COPD is often misdiagnosed. Key differentials to consider:

Asthma

COPD-Asthma Overlap (ACO): Some patients exhibit features of both conditions (~15-20%); typically higher eosinophils, more reversibility, better response to ICS.

Heart Failure

Both cause dyspnoea, orthopnoea, reduced exercise tolerance, and ankle swelling. Key discriminators:

IMPORTANT: COPD and heart failure frequently coexist (shared risk factors, chronic hypoxia contributing to LV dysfunction).

Bronchiectasis

Can coexist with COPD ("bronchiectasis-COPD overlap").

Interstitial Lung Disease (ILD)

Other Differentials

• Tuberculosis: Cough, weight loss, night sweats, haemoptysis; endemic areas; CXR upper lobe cavitation
• Lung cancer: Haemoptysis, weight loss, chest pain; CXR/CT mass/nodule
• Obliterative bronchiolitis: Young patient, history of toxic exposure (nitrogen dioxide, sulfur dioxide) or post-transplant
• Primary pulmonary hypertension: Young woman, severe dyspnoea, loud P2, clear lung fields

---

9. Special Populations

Alpha-1 Antitrypsin Deficiency

See dedicated topic. Key points:

• Autosomal recessive; PiZZ phenotype most severe
• Early-onset emphysema (age 30-50), particularly in smokers
• Lower lobe predominant on CT (vs upper lobe in smoking-related COPD)
• Test AAT levels in: age less than 45, minimal smoking, family history, liver disease
• Management: As per standard COPD + AAT augmentation therapy (IV infusions; slows decline if started early)

COPD in Women

• Women may be more susceptible to tobacco smoke for equivalent exposure
• Develop COPD at younger ages and with fewer pack-years
• May have different symptom presentation (more dyspnoea, less sputum)
• Osteoporosis risk higher

Younger Patients (less than 50 years)

• Consider alternative diagnoses: asthma, alpha-1 antitrypsin deficiency, obliterative bronchiolitis, bronchiectasis
• If confirmed COPD: aggressive risk factor modification, consider AAT testing, genetic counselling

---

10. Key Guidelines and Recommendations Summary

---

11. Patient Information and Self-Management

Understanding COPD

COPD is a long-term lung condition that makes breathing difficult. The airways become narrowed and damaged, making it harder for air to flow in and out. The most common cause is smoking, though not all smokers develop COPD, and some non-smokers can develop it due to other exposures.

What Can You Do?

Stop Smoking: This is the MOST important action. It slows disease progression and improves symptoms. Speak to your doctor about stop-smoking medications and support.

Take Your Inhalers Correctly: Incorrect technique means medications don't reach your lungs. Ask for demonstration and regular checks.

Stay Active: Exercise improves breathing and overall health. Pulmonary rehabilitation programmes are highly beneficial.

Get Vaccinated: Annual flu vaccine and pneumonia vaccine reduce infection risk.

Recognise Exacerbations: Increased breathlessness, sputum volume/purulence, wheeze. Have a self-management plan with rescue medications.

Manage Comorbidities: Control blood pressure, diabetes, heart disease.

---

12. Examination Focus (MRCP/FRACP/Postgraduate)

PACES/Clinical Examination

Common PACES Scenario: "Examine this patient's respiratory system"

• stable COPD patient

Positive Findings to Elicit:

• Inspection: Cachexia, pursed-lip breathing, barrel chest, accessory muscle use
• Palpation: Reduced chest expansion
• Percussion: Hyperresonant, low diaphragm
• Auscultation: Reduced breath sounds, wheeze, prolonged expiration

Discussion Points:

• Confirm diagnosis with spirometry (FEV1/FVC less than 0.70 post-BD)
• Assess severity (GOLD grade, ABCD group)
• Discuss management: smoking cessation, bronchodilators (LAMA>LABA), pulmonary rehab, vaccination
• Indications for ICS (eosinophils ≥300 + frequent exacerbations)
• LTOT criteria
• Complications: cor pulmonale, respiratory failure, lung cancer

Viva Topics

"How do you diagnose COPD?"

• Clinical suspicion: age > 40, smoking history, dyspnoea, chronic cough
• Confirm with post-bronchodilator spirometry: FEV1/FVC less than 0.70
• Assess severity with FEV1 % predicted (GOLD 1-4)
• Classify treatment group with symptoms (mMRC/CAT) and exacerbation history (GOLD ABCD)

"What is the most effective intervention in COPD?"

• Smoking cessation - only intervention proven to slow FEV1 decline and reduce mortality
• Offer combination of behavioural support and pharmacotherapy (varenicline, NRT, bupropion)

"When would you use inhaled corticosteroids in COPD?"

• NOT first-line (unlike asthma)
• Indications: Frequent exacerbations (≥2/year) AND blood eosinophils ≥300 cells/μL
• Increases pneumonia risk (~50% relative increase)
• Can be withdrawn in patients without appropriate indications

"What are the criteria for long-term oxygen therapy?"

• Severe hypoxaemia: PaO2 ≤7.3 kPa OR SpO2 ≤88%
• Moderate hypoxaemia (PaO2 7.3-8.0 kPa) PLUS cor pulmonale, polycythaemia, or pulmonary hypertension
• TWO assessments ≥3 weeks apart, stable, on optimal therapy
• Requires ≥15 hours daily use
• Does NOT benefit moderate desaturation (SpO2 89-93%)

"What is the BODE index?"

• Multidimensional prognostic tool: BMI, Obstruction (FEV1), Dyspnoea (mMRC), Exercise (6MWT)
• Superior to FEV1 alone for predicting mortality
• Score 0-10; higher = worse prognosis

---

13. Recent Advances and Evolving Evidence

Triple Therapy Reappraisal: The indiscriminate use of ICS/LAMA/LABA triple therapy is being reconsidered. Current evidence supports targeted use based on eosinophil count and exacerbation phenotype rather than universal application in severe COPD. [11]

Eosinophil-Guided Therapy: Blood eosinophil count emerging as biomarker to guide ICS use; ≥300 cells/μL identifies patients likely to benefit from ICS; less than 100 cells/μL suggests minimal benefit and potentially increased harm. [10]

LTOT Duration: Recent NEJM trial (2024) challenges traditional ≥18-hour LTOT requirement, suggesting 15 hours may be non-inferior to 24 hours for severe hypoxaemia. [15]

Biologics in COPD: Unlike asthma, biologic therapies (anti-IL-5, anti-IgE) have shown limited benefit in COPD. Ongoing research in specific phenotypes (eosinophilic COPD, frequent exacerbators).

Lung Microbiome: Emerging understanding of lung microbiome changes in COPD may inform future therapeutic strategies (beyond simple bacterial infection paradigm).

---

14. References

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2024 Report. PMID: 38941078

2. Stolz D, Mkorombindo T, Schumann DM, et al. Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. Lancet. 2022;400(10356):921-972. PMID: 36075255

3. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138(1):16-27.

4. Wedzicha JA, Miravitlles M, Hurst JR, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017;49(3):1600791. PMID: 28298398

5. Miravitlles M, Vogelmeier C, Roche N, et al. A review of national guidelines for management of COPD in Europe. Eur Respir J. 2016;47(2):625-637. PMID: 26797035

6. Adeloye D, Song P, Zhu Y, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. 2022;10(5):447-458.

7. Eisner MD, Anthonisen N, Coultas D, et al. An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182(5):693-718.

8. American Thoracic Society/European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818-900.

9. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med. 2002;166(5):675-679.

10. Calzetta L, Matera MG, Braido F, et al. Adding a LAMA to ICS/LABA therapy: A meta-analysis of triple combination therapy in COPD. Chest. 2019;155(4):758-770. PMID: 30660781

11. Vanfleteren LE, Ullman A, Nordenson A, et al. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. Int J Chron Obstruct Pulmon Dis. 2018;13:3971-3981. PMID: 30587953

12. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005-1012.

13. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease (TORCH). N Engl J Med. 2007;356(8):775-789. PMID: 17314337

14. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188(8):e13-e64.

15. Ekström M, Bornefalk H, Lind F, et al. Long-Term Oxygen Therapy for 24 or 15 Hours per Day in Severe Hypoxemia. N Engl J Med. 2024;391(12):1131-1141. PMID: 39254466

16. Long-Term Oxygen Treatment Trial Research Group. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med. 2016;375(17):1617-1627. PMID: 27783918

17. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689-698.

18. Mannino DM, Gagnon RC, Petty TL, et al. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2000;160(11):1683-1689.

19. Ford ES, Murphy LB, Khavjou O, et al. Total and state-specific medical and absenteeism costs of COPD among adults aged ≥18 years in the United States for 2010 and projections through 2020. Chest. 2015;147(1):31-45.

20. Aryal S, Diaz-Guzman E, Mannino DM. COPD and gender differences: an update. Transl Res. 2013;162(4):208-218.

21. O'Donnell DE, Laveneziana P, Webb K, et al. Chronic obstructive pulmonary disease: clinical integrative physiology. Clin Chest Med. 2014;35(1):51-69.

---